WHO ICTRP trial
Nivolumab in combination with temozolomide and radiotherapy in children and…
EUCTR2018-002688-24-FR · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-002688-24-FR |
|---|---|
| Public title | Nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma |
| Scientific title | Phase I-II study of nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma - NIVOGLIO |
| Primary sponsor | Gustave Roussy |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;Italy;United Kingdom |
| Conditions | Newly diagnosed High-Grade Gliomas (HGG) MedDRA version: 20.0 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version… |
| Interventions | Product Name: Nivolumab Product Code: BMS-936558 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Nivolumab Other descriptive name: NIVOLUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal… |
| Registration date | Feb 20, 2019 |
| Target size | 40 |
| Secondary IDs | 2018/2797 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: